메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Jun Ho Yi (Chung-Ang University Hospital) 이경원 (경상국립대학교) 이지현 (동아대학교) Kwai Han Yoo (Division of Hematology-Oncology, Gachon University College of Medicine) Chul Won Jung (Sungkyunkwan University School of Medicine) Dae Sik Kim (Korea University Guro Hospital) Jeong-Ok Lee (Department of Internal Medicine Seoul National University Bundang Hospital) Hyeon Seok Eom (National Cancer Center) Ja Min Byun (Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National Univer) Youngil Koh (Department of Hematology/Oncology Seoul National University Hospital) Sung Soo Yoon (Seoul National University Hospital) Jin Seok Kim (Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University Coll) Jee Hyun Kong (Yonsei University Wonju College of Medicine) Ho-Young Yhim (Department of Hematology/Oncology Jeonbuk National University Hospital) Deok Hwan Yang (Chonnam National University Hwasun Hospital) Dok Hyun Yoon (Asan Medical Center) Do Hyoung Lim (Division of Hematology-Oncology, Department of Medicine, Dankook University College of Medicine) Won Sik Lee (Inje University Busan Baik Hospital) Ho Jin Shin (Department of Hematology/Oncology Pusan National University Hospital)
저널정보
대한혈액학회 Blood Research Blood Research Vol.56 No.4
발행연도
2021.12
수록면
243 - 251 (9page)
DOI
10.5045/br.2021.2021102

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western countries but is rare in the East Asian countries. Due to its rarity and the lack of feasible novel agents and laboratory prognostic tools, there are limited data on the clinical outcomes of this disease in Asia. To clarify the current treatment status, we performed a multicenter retrospective analysis of patients with CLL in Korea. Methods The medical records of 192 eligible patients between 2008 and 2019 were reviewed for clinical characteristics, treatment courses, and outcomes. The first-line treatment regimens of the patients included in this analysis were as follows: fludarabine/cyclophosphamide/ rituximab (FCR) (N=117, 52.7%), obinutuzumab plus chlorambucil (GC) (N=30, 13.5%), and chlorambucil monotherapy (N=24, 10.8%). Results The median progression-free survival (PFS) was 55.6 months, and the average 2-year PFS rate was 80.3%. PFS was not significantly different between the patients receiving FCR and those receiving GC; however, chlorambucil treatment was associated with significantly inferior PFS (P <0.001). The median overall survival was 136.3 months, and the average 5- and 10-year OS rates were 82.0% and 57.4%, respectively. Conclusion This is one of the largest studies involving Korean patients with CLL. Although the patients had been treated with less favored treatment regimens, the outcomes were not different from those reported in Western studies.

목차

등록된 정보가 없습니다.

참고문헌 (30)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0